Media Contact:
Nicole Osmer
nicole@nicoleosmer.com
(650) 454-0504

Tryton Announces Clinical Presentations at TCT Conference in San Francisco
Company to Exhibit at TCT in Booth #1927

Durham, N.C. – Nov. 2, 2011 – Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced activities highlighting the latest experience with the TRYTON Side Branch Stent at the annual Transcatheter Cardiovascular Therapeutics (TCT) 2011 conference taking place Nov. 7-11 in San Francisco.

"We look forward to a number of presentations revealing new clinical data involving the Tryton Side Branch Stent at TCT, adding to our previously published data of more than 700 patients with consistent TLR rates of less than 4% at greater than six months follow up," said Shawn P. McCarthy, president and CEO of Tryton Medical. "We are also excited to share our progress in the TRYTON randomized, controlled IDE, with more than 175 patients enrolled. All of this evidence bolsters our physicians' clinical adoption and routine use, now with approximately 3,500 implants across Europe, the Middle East, and Russia."

On Monday November 7 at 10:46 a.m., Martin B. Leon, M.D., professor of Medicine and director of the Center for Interventional Vascular Therapy at Columbia University Medical Center, will present "**TRYTON: Design and Status of the First U.S. IDE Dedicated Bifurcation Stent Trial**" in Room 133 at the Moscone Convention Center as part of the Advanced Operator's Workshop: Left Main and Bifurcation Stenting. Dr. Leon serves as principal investigator of the Tryton IDE Study.

On Tuesday November 8 at 7:00 a.m., a clinical symposium entitled "**Built For Bifurcation: Tryton Experience in the United States and Europe**" will feature a comprehensive overview of Tryton clinical evidence with a number of leading clinicians in Room 120 of the Moscone Convention Center. The event is co-chaired by Thierry Lefèvre, M.D., of the Institut Hospitalier Jacques Cartier in Massy, France; and William Fearon, M.D., associate professor of Cardiovascular Medicine at Stanford University School of Medicine.

- Dr. Fearon will present an overview of the Tryton IDE clinical study, the first-ever dedicated bifurcation device to be evaluated in an FDA study.
- Yaron Almagor, M.D., of Shaare Zedek Medical Center in Jerusalem, Israel, will review the excellent growing clinical registry data from more than 700 patients with 4% target lesion revascularization and low stent thrombosis rates.
- Prof. Antonio Bartorelli. M.D, of the University of Milan, will discuss ostial coverage by IVUS analysis.
- Prof. David P. Foley, M.D., of Beaumont Hospital & Royal College of Surgeons in Ireland, will discuss his extensive clinical follow up series of 200 patients.
- Maciej Lesiak, M.D., of the University Hospital in Poznan, Poland, will share his left main treatment experience with Tryton.

TRYTON MEDICAL, INC.
1000 Park Forty Plaza, Suite 325
Durham, NC 27713

PHONE 919/226.1490
FAX 919/226.1497
info@trytonmedical.com

trytonmedical.com

Several additional **TCT poster abstracts will highlight the Tryton stent** on Tuesday, Nov. 8, 8:00 – 10:00 a.m. in Hall D, including:

- Michael Norell, M.D., of the Heart and Lung Centre – The Royal Wolverhampton NHS Trust: Single center clinical experience with Tryton.
- Michael Magro, M.D., of the Thoraxcenter, Erasmus Medical Center in Rotterdam, the Netherlands: Review of a Tryton left main registry.
- Eulogio Garcia, M.D., of the Hospital Clinico San Carlos in Madrid, Spain: Results of an E-Tryton Spanish registry.
- Solomon Asgedom, M.D., of the Beaumont Hospital in Dublin, Ireland: Coronary artery bifurcation stenting using a dedicated side branch stent combined with DES: Two years clinical outcome.

The company will be participating in TCT as an exhibitor in booth #1927.

About Coronary Bifurcation Disease
Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation.[i] In patients undergoing PCI-stenting, approximately one-third has a bifurcation lesion. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions.

About the Tryton Side Branch Stent
The Tryton Side Branch Stent System is built for bifurcation using proprietary Tri-zone™ technology to offer a dedicated strategy for treating bifurcation lesions. Tryton's cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.
The stent system has received CE Mark and is commercially available throughout Europe, Russia and the Middle East. It is approved in the United States for investigational use only.

About Tryton Medical, Inc.
Tryton Medical, Inc., located in Durham, N.C., is a leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D. (professor of medicine at Dartmouth Medical School/Dartmouth- Hitchcock Medical Center) and Dan Cole to develop stents for the definitive treatment of bifurcation lesions. The Tryton Side Branch Stent System, approved for sale in Europe, is designed to offer a dedicated strategy for treating these challenging cases. Privately held, Tryton is backed by Arnerich Massena & Associates, Spray Ventures, PTV Sciences, and RiverVest Ventures. For more information please visit www.trytonmedical.com.

# # #

[i] Scot Garg, et al. EuroIntervention 2011:6: 928-935. Available online at http://www.pcronline.com/eurointervention/34th_issue/162/